Combination Of Camonsertib Plus Parpi Shows Clinical Activity In Ddr-Aberrant Tumours

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Investigating the ATR inhibitor elimusertib in advanced solid tumors

Target Practice: Understanding How PARP Inhibitors Take Aim at DDR Mutations Across Solid Tumors

PeerView Oncology

Assessing cabozantinib with PARP inhibitors in DDR mutant-tumors

JAVELIN PARP Medley: Combining PARP inhibitors and immune checkpoint inhibitors

Niraparib in BAP1 and DDR pathway deficient solid tumors

Dr. Litton on the Impact of PARP Inhibitors in Breast Cancer

Dr. Emens on the Combination of Checkpoint Inhibitors and PARP Inhibitors in Ovarian Cancer

ASCP Tumor Board Simulation - Immune-Related Adverse Events

ASCP

Overcoming resistance to PARP inhibition in ovarian cancer

BRAFi and combinations

Use of PARP1-selective and ATR inhibitors to target DDR signalling pathway

Barriers to PARP Inhibitors Plus Androgen Receptor-Targeted Agents in Earlier Treatment Settings

GU Oncology Now

I/O Combination Strategies in Ovarian Cancer

Dr. Moore on Immunotherapy and PARP Combinations in BRCA-Mutated Ovarian Cancer

Expert Perspectives: The Clinical Potential of PARP Inhibitors in Ovarian Cancer

Round-table discussion on PARP inhibitor

European Association of Urology

Combination of Veliparib and Chemotherapy in BRCA-Positive Breast Cancer

Targeted Oncology

Combinations With PARP Inhibitors for Ovarian Cancer